DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: AS101-Loaded PLGA–PEG Nanoparticles for Autoimmune Regulation and Chemosensitization

Abstract

The in vivo delivery of therapeutic nanoparticles (NPs) represents a potentially powerful tool that can significantly alter the biological effects of pharmaceutically active compounds. Here, we report on sensitization of tumors to chemotherapy by ammonium trichloro(dioxoethyleneo, o’)tellurate (AS101) encapsulated in NPs, termed AS101-NPs, developed as a composite with the biocompatible and biodegradable copolymer of poly(D,L-lactic-co-glycolic acid)- block-poly(ethylene glycol) (PLGA-b-PEG). AS101 is a potent immunomodulating agent (both in vitro and in vivo) currently undergoing phase II clinical trials for anti-tumor activity and sensitization of tumors to chemotherapy. Approaches that can control the pharmacokinetic parameters to regulate its clearance from the administered drug delivery system and minimize side effects are of prodigious importance. A strategy to synthesize AS101-NPs by nanoprecipitation is presented, along with their physical characterization. The influence of AS101 encapsulation on its properties was evaluated in vivo. The AS101-NPs demonstrated significantly enhanced peritoneal macrophage count compared with AS101 administered in vivo at conventional dosage in mouse models. Moreover, AS101 inhibited B16 melanoma lung metastasis in mice when given intraperitoneally, before or after tumor cell inoculation. A bellshaped dose-response was observed. The frequency of AS101 administration appears to be an important factor for achieving optimal antimetastatic effect.

Authors:
 [1]; ORCiD logo [1];  [1];  [1]; ORCiD logo [1]
  1. Bar-Ilan Univ., Ramat-Gan (Israel)
Publication Date:
Research Org.:
Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1544701
Report Number(s):
LA-UR-19-23090
Journal ID: ISSN 2576-6422
Grant/Contract Number:  
89233218CNA000001
Resource Type:
Accepted Manuscript
Journal Name:
ACS Applied Bio Materials
Additional Journal Information:
Journal Volume: 2; Journal Issue: 5; Journal ID: ISSN 2576-6422
Publisher:
ACS Publications
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; Material Science

Citation Formats

Mishra, Rahul Kumar, Kumar, Vijay Bhooshan, Monteran, Lea, Sredni, Benjamin, and Gedanken, Aharon. AS101-Loaded PLGA–PEG Nanoparticles for Autoimmune Regulation and Chemosensitization. United States: N. p., 2019. Web. doi:10.1021/acsabm.9b00200.
Mishra, Rahul Kumar, Kumar, Vijay Bhooshan, Monteran, Lea, Sredni, Benjamin, & Gedanken, Aharon. AS101-Loaded PLGA–PEG Nanoparticles for Autoimmune Regulation and Chemosensitization. United States. https://doi.org/10.1021/acsabm.9b00200
Mishra, Rahul Kumar, Kumar, Vijay Bhooshan, Monteran, Lea, Sredni, Benjamin, and Gedanken, Aharon. Fri . "AS101-Loaded PLGA–PEG Nanoparticles for Autoimmune Regulation and Chemosensitization". United States. https://doi.org/10.1021/acsabm.9b00200. https://www.osti.gov/servlets/purl/1544701.
@article{osti_1544701,
title = {AS101-Loaded PLGA–PEG Nanoparticles for Autoimmune Regulation and Chemosensitization},
author = {Mishra, Rahul Kumar and Kumar, Vijay Bhooshan and Monteran, Lea and Sredni, Benjamin and Gedanken, Aharon},
abstractNote = {The in vivo delivery of therapeutic nanoparticles (NPs) represents a potentially powerful tool that can significantly alter the biological effects of pharmaceutically active compounds. Here, we report on sensitization of tumors to chemotherapy by ammonium trichloro(dioxoethyleneo, o’)tellurate (AS101) encapsulated in NPs, termed AS101-NPs, developed as a composite with the biocompatible and biodegradable copolymer of poly(D,L-lactic-co-glycolic acid)- block-poly(ethylene glycol) (PLGA-b-PEG). AS101 is a potent immunomodulating agent (both in vitro and in vivo) currently undergoing phase II clinical trials for anti-tumor activity and sensitization of tumors to chemotherapy. Approaches that can control the pharmacokinetic parameters to regulate its clearance from the administered drug delivery system and minimize side effects are of prodigious importance. A strategy to synthesize AS101-NPs by nanoprecipitation is presented, along with their physical characterization. The influence of AS101 encapsulation on its properties was evaluated in vivo. The AS101-NPs demonstrated significantly enhanced peritoneal macrophage count compared with AS101 administered in vivo at conventional dosage in mouse models. Moreover, AS101 inhibited B16 melanoma lung metastasis in mice when given intraperitoneally, before or after tumor cell inoculation. A bellshaped dose-response was observed. The frequency of AS101 administration appears to be an important factor for achieving optimal antimetastatic effect.},
doi = {10.1021/acsabm.9b00200},
journal = {ACS Applied Bio Materials},
number = 5,
volume = 2,
place = {United States},
year = {2019},
month = {4}
}

Works referenced in this record:

Biologic response modifiers: Indications, implications, and insights
journal, May 2017

  • Davis, Benjamin P.; Ballas, Zuhair K.
  • Journal of Allergy and Clinical Immunology, Vol. 139, Issue 5
  • DOI: 10.1016/j.jaci.2017.02.013

Synthesis and Properties of Ammonium Trichloro(dioxyethylene- O , O ′)tellurate (AS-101). A New Immunomodulating Compound
journal, January 1989


Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide.
journal, September 1995


Optical trapping and manipulation of single cells using infrared laser beams
journal, December 1987

  • Ashkin, A.; Dziedzic, J. M.; Yamane, T.
  • Nature, Vol. 330, Issue 6150
  • DOI: 10.1038/330769a0

Evaluation of anti-cancer and immunomodulatory effects of carnosol in a Balb/c WEHI-164 fibrosarcoma model
journal, July 2014

  • Rahnama, Maryam; Mahmoudi, Mahmoud; Zamani Taghizadeh Rabe, Shahrzad
  • Journal of Immunotoxicology, Vol. 12, Issue 3
  • DOI: 10.3109/1547691X.2014.934975

Designing idiosyncratic hmPCL -siRNA nanoformulated capsules for silencing and cancer therapy
journal, April 2016

  • Kumar, Vijay Bhooshon; Medhi, Himadri; Yong, Zhang
  • Nanomedicine: Nanotechnology, Biology and Medicine, Vol. 12, Issue 3
  • DOI: 10.1016/j.nano.2015.10.007

Encapsulation of Natural Polyphenolic Compounds; a Review
journal, November 2011


Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
journal, January 2012

  • Kamaly, Nazila; Xiao, Zeyu; Valencia, Pedro M.
  • Chemical Society Reviews, Vol. 41, Issue 7
  • DOI: 10.1039/c2cs15344k

Nanomedicine: Developing smarter therapeutic and diagnostic modalities☆
journal, December 2006


Nanoparticle-mediated cellular response is size-dependent
journal, March 2008

  • Jiang, Wen; Kim, Betty Y. S.; Rutka, James T.
  • Nature Nanotechnology, Vol. 3, Issue 3
  • DOI: 10.1038/nnano.2008.30

Cancer nanotechnology: opportunities and challenges
journal, March 2005

  • Ferrari, Mauro
  • Nature Reviews Cancer, Vol. 5, Issue 3, p. 161-171
  • DOI: 10.1038/nrc1566

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
journal, October 2008

  • Dhar, S.; Gu, F. X.; Langer, R.
  • Proceedings of the National Academy of Sciences, Vol. 105, Issue 45
  • DOI: 10.1073/pnas.0809154105

Soluble Single-Walled Carbon Nanotubes as Longboat Delivery Systems for Platinum(IV) Anticancer Drug Design
journal, July 2007

  • Feazell, Rodney P.; Nakayama-Ratchford, Nozomi; Dai, Hongjie
  • Journal of the American Chemical Society, Vol. 129, Issue 27
  • DOI: 10.1021/ja073231f

Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells
journal, May 2012


Conjugated Platinum(IV)−Peptide Complexes for Targeting Angiogenic Tumor Vasculature
journal, September 2007

  • Mukhopadhyay, Sumitra; Barnés, Carmen M.; Haskel, Ariel
  • Bioconjugate Chemistry, Vol. 19, Issue 1
  • DOI: 10.1021/bc070031k

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo
journal, January 2011

  • Dhar, Shanta; Kolishetti, Nagesh; Lippard, Stephen J.
  • Proceedings of the National Academy of Sciences, Vol. 108, Issue 5
  • DOI: 10.1073/pnas.1011379108

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy
journal, October 2010

  • Kolishetti, N.; Dhar, S.; Valencia, P. M.
  • Proceedings of the National Academy of Sciences, Vol. 107, Issue 42
  • DOI: 10.1073/pnas.1011368107

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
journal, April 2012


Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
journal, October 2012

  • Zhang, Xue-Qing; Xu, Xiaoyang; Bertrand, Nicolas
  • Advanced Drug Delivery Reviews, Vol. 64, Issue 13
  • DOI: 10.1016/j.addr.2012.08.005

The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
journal, October 2008

  • Fishburn, C. Simone
  • Journal of Pharmaceutical Sciences, Vol. 97, Issue 10
  • DOI: 10.1002/jps.21278

Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface
journal, October 1980


Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation
journal, October 2011

  • Shi, Jinjun; Xiao, Zeyu; Kamaly, Nazila
  • Accounts of Chemical Research, Vol. 44, Issue 10
  • DOI: 10.1021/ar200054n

Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof on In Vivo Properties
journal, May 2013

  • Johnstone, Timothy C.; Kulak, Nora; Pridgen, Eric M.
  • ACS Nano, Vol. 7, Issue 7
  • DOI: 10.1021/nn401905g

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
journal, April 2006

  • Farokhzad, O. C.; Cheng, J.; Teply, B. A.
  • Proceedings of the National Academy of Sciences, Vol. 103, Issue 16
  • DOI: 10.1073/pnas.0601755103

Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery
journal, February 2007


Engineered nanomedicine for myeloma and bone microenvironment targeting
journal, June 2014

  • Swami, A.; Reagan, M. R.; Basto, P.
  • Proceedings of the National Academy of Sciences, Vol. 111, Issue 28
  • DOI: 10.1073/pnas.1401337111

Works referencing / citing this record:

Improving the Li–S battery performance by applying a combined interface engineering approach on the Li 2 S cathode
journal, January 2019

  • Hao, Junran; Pan, Yuede; Chen, Weihua
  • Journal of Materials Chemistry A, Vol. 7, Issue 48
  • DOI: 10.1039/c9ta10301e